Combination Chemotherapy With or Without G-CSF in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed primary stage III, stage IV, or recurrent endometrial carcinoma
• * Very poor potential for cure by radiotherapy or surgery alone or in combination
• Measurable disease
• * Disease in an irradiated field as the only site of measurable disease allowed provided there has been clear progression since completion of radiotherapy
• PATIENT CHARACTERISTICS:
• Age
• 18 and over
• Performance status
• GOG 0-2
• Life expectancy
• Not specified
• Hematopoietic
• Platelet count at least 100,000/mm\^3
• Granulocyte count at least 1,500/mm\^3
• Hepatic
• SGPT no greater than 3 times upper limit of normal
• Bilirubin normal
• Renal
• Creatinine no greater than 1.6 mg/dL
• Cardiovascular
• LVEF at least 50% within past 6 months
• No uncontrolled angina
• No third-degree or complete heart block unless a pacemaker is in place
• Neurologic
• No serious peripheral neuropathy
• Other
• No prior or concurrent malignancy within past 5 years except nonmelanoma skin cancer
• No uncontrolled infection
• No sensitivity to E. coli-derived drug preparations
• PRIOR CONCURRENT THERAPY:
• Biologic therapy
• Prior biologic therapy allowed
• No concurrent biologic therapy
• Chemotherapy
• No prior cytotoxic chemotherapy, including chemotherapy used for radiation sensitization
• No prior chemotherapy for any prior malignancy
• Endocrine therapy
• Prior hormone therapy allowed
• No concurrent hormone therapy
• Radiotherapy
• At least 4 weeks since prior radiotherapy to the whole pelvis or to over 50% of the spine
• Surgery
• Not specified